SHR-A2102 is named as an intervention in 15 current clinical trials in our China register. 14 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Shanghai Hengrui Pharmaceutical Co., Ltd (8). The most-studied condition is Advanced Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
NCT06738251 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma
|
Phase 3 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer
|
Phase 2 | Recruiting | Fudan University | China |
|
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor
|
Phase 2 | Recruiting | Fudan University | China |
|
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
NCT06547736 · ClinicalTrials.gov ↗ · Pancreatic Cancer
|
Phase 2 | Recruiting | Fudan University | China |
|
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)
|
Phase 2 | Recruiting | Fudan University | China |
|
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
NCT06654440 · ClinicalTrials.gov ↗ · Advanced Gynecological Malignancy
|
Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
NCT06895928 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
NCT07175220 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
NCT07229729 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
|
Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
NCT06512051 · ClinicalTrials.gov ↗ · Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06589778 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 1/2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
NCT06639347 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma
|
Phase 1/2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
NCT07059221 · ClinicalTrials.gov ↗ · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 1/2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | China |
|
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
NCT07041437 · ClinicalTrials.gov ↗ · Advanced Breast Cancer
|
Phase 2 | Not yet open | Fudan University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Breast Cancer | 2 |
| Advanced Solid Tumors | 2 |
| HER2-negative Breast Cancer | 2 |
| Advanced Urothelial Carcinoma | 2 |
| Non-Small Cell Lung Cancer | 1 |
| Breast Neoplasm | 1 |
| Breast Cancer | 1 |
| Hormone Receptor Positive Tumor | 1 |
| Advanced Gynecological Malignancy | 1 |
| Non-small Cell Lung Cancer | 1 |
| Pancreatic Cancer | 1 |
| Triple-negative Breast Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Triple Negative Breast Cancer (TNBC) | 1 |
| Locally Advanced or Metastatic Non-small Cell Lung Cancer | 1 |
| Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 1 |
| Advanced or Metastatic Non-small Cell Lung Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 8 |
| Fudan University | 5 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 15 | 14 |
A trial with sites in more than one country appears in each of those registers.
15 current trials in our China register name SHR-A2102 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 14 of the 15 trials are recruiting: 14 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Hengrui Pharmaceutical Co., Ltd (8), Fudan University (5), Jiangsu HengRui Medicine Co., Ltd (1) and Suzhou Suncadia Biopharmaceuticals Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SHR-A2102 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SHR-A2102 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SHR-A2102 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.